Lung injury with one-lung ventilation
Conditions
Interventions
Normal saline group (Group C):100ml of normal saline, administered entirely by intravenous drip within 10 minutes after tracheal intubation
Edaravone group (group E):Group E:Edaravone 0.8mg/kg administered intravenously over 100ml of normal saline within 10 minutes of endotracheal intubation.
Dexamethasone group (group D):Group D: dexamethasone 0.2mg/kg was added to normal saline, a total of 100ml, and all intravenous injections were given within 10 minutes
dexamethasone combined with Edaravone group (group D+E):Group D+E: 0.2mg/kg of dexamethasone and 0.8mg/kg of edaravone are added to 100ml of normal saline and all are administered via intravenous infu
Sponsors
The Second Affiliated Hospital of Xi 'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-70 years old; 2.Body mass index 19-30 kg/m^2; 3.ASA Class I-III; 4. Single lung ventilation time >1 hour; 5. Preoperative lung function was generally normal; 6. Thoracotomy/thoracoscopic lobectomy or esophageal surgery should be performed at an appropriate time.
Exclusion criteria
Exclusion criteria: 1. Patients with preoperative immune system diseases and/or those who have used drugs that regulate immune function (such as steroid hormones) within 6 weeks before surgery; 2. Patients with severe systemic diseases; 3. Patients allergic to the trial drug or with other contraindications; 4. Patients with fever before surgery; 5. Patients with a history of pulmonary infection or chronic pulmonary disease; 6. Patients whose pulse oxygen saturation (SPO2) during one-lung ventilation (OLV) cannot be maintained above 95%; 7. Patients who need to use corticosteroids or other membrane stabilizers due to emergency situations during surgery; 8. Patients with significant intraoperative bleeding, unstable hemodynamics that are difficult to maintain, and large amounts of blood and fluid transfusion; 9.patients who undergo cardiopulmonary resuscitation or other rescue measures during surgery; 10. Patients who have stopped smoking for less than 2 weeks before surgery; 11.Participated in other clinical studies in the past 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pulmonary complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentrations of TNF-a, SOD, MDA in BALF;IL-6 in plasma; | — |
Countries
China
Contacts
Public ContactZhang Pengbo
The Second Affiliated Hospital of Xi 'an Jiaotong University
Outcome results
None listed